Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07143669 · ClinicalTrials.gov registry record
Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations
A clinical trial of KIT D816V Mutation and Clonal Mast Cell Disease, sponsored by Blueprint Medicines Corporation.
- Recruiting
- Registry status
- 450
- Enrollment target
- 14
- Study locations
NCT07143669: Recruiting study of KIT D816V Mutation and Clonal Mast Cell Disease, sponsored by Blueprint Medicines Corporation.
NCT07143669 is a study of KIT D816V Mutation and Clonal Mast Cell Disease that is actively recruiting participants, run by Blueprint Medicines Corporation. The registered enrollment target is 450 participants. The trial reports 14 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07143669, a study of KIT D816V Mutation and Clonal Mast Cell Disease, is actively recruiting participants, sponsored by Blueprint Medicines Corporation.
- RECRUITING
- Registry status
- 450 participants
- Enrollment target
- 14
- Study locations
Study Summary
This is a multicenter screening study to characterize the prevalence of the KIT D816V mutation in participants with suspected clonal mast cell disease.
Conditions Studied
Interventions
- OTHER Screening
Study Locations (14)
California
- Kaiser Permanente San Diego - San Diego
- Allergy & Asthma Clinical Research of the Bay Area - Walnut Creek
Alabama
- AllerVie Clinical Research - Birmingham
Florida
- Allergy, Asthma, & Immunology Associates of Tampa Bay - Tampa
Georgia
- Emory University - Atlanta
Illinois
- Midwest Allergy Sinus Asthma - Normal
Maryland
- AllerVie Health - Glenn Dale
Missouri
- Barnes-Jewish West County Hospital - St Louis
Nebraska
- Somnos Clinical Research - Lincoln
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 450 participants |
| Start Date | 2025-10-17 |
| Est. Completion | 2028-10-31 |
What NCT07143669 shows while recruiting
NCT07143669 is an observational study that tracks outcomes without assigning an intervention. The registered 450 participants enrollment target is mid-sized for trials with a published cap.
The record links to 3 conditions, with KIT D816V Mutation appearing as the primary indexed condition, and to 1 intervention - of which Screening is the first listed.
NCT07143669 lists 14 locations in 13 states (California, Alabama, Florida).
Frequently Asked Questions
What is clinical trial NCT07143669 about?
NCT07143669 is a clinical study titled "Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations". This is a multicenter screening study to characterize the prevalence of the KIT D816V mutation in participants with suspected clonal mast cell disease.
What is the current status of trial NCT07143669?
This trial is currently recruiting. The enrollment target is 450 participants. The study started on 2025-10-17. Estimated completion is 2028-10-31.
What conditions does trial NCT07143669 study?
This clinical trial studies the following conditions: KIT D816V Mutation, Clonal Mast Cell Disease, Suspected KITD816V Mutated Clonal Mast Cell Disease.
What interventions are being tested in trial NCT07143669?
The interventions under investigation include: Screening (OTHER).
Who is sponsoring clinical trial NCT07143669?
This trial is sponsored by Blueprint Medicines Corporation, which has 24 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07143669 being conducted?
This trial has 14 study locations across Alabama, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for KIT D816V Mutation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00515060 · 450 participants
Psychophysical Studies of Cancer Therapy Pain
- NCT01257269 · 450 participants
Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)
- NCT03047161 · 450 participants
Electrophysiology of Fetal Arrhythmia
- NCT03269630 · 450 participants
New Orleans Pulmonary Hypertension Biobank
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI